Assertio officially announced its definitive agreement to acquire Spectrum Pharmaceuticals on April 25, 2023, and successfully completed the strategic transaction later that year. This all-stock merger brought Spectrum's commercial-stage oncology assets—notably the novel treatment Rolvedon—under Assertio's corporate portfolio, expanding its commercial footprint into the targeted oncology therapeutic market.